GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ASKA Pharmaceutical Holdings Co Ltd (TSE:4886) » Definitions » Gross Profit

ASKA Pharmaceutical Holdings Co (TSE:4886) Gross Profit : 円30,664 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is ASKA Pharmaceutical Holdings Co Gross Profit?

ASKA Pharmaceutical Holdings Co's gross profit for the three months ended in Dec. 2023 was 円8,445 Mil. ASKA Pharmaceutical Holdings Co's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was 円30,664 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. ASKA Pharmaceutical Holdings Co's gross profit for the three months ended in Dec. 2023 was 円8,445 Mil. ASKA Pharmaceutical Holdings Co's Revenue for the three months ended in Dec. 2023 was 円17,176 Mil. Therefore, ASKA Pharmaceutical Holdings Co's Gross Margin % for the quarter that ended in Dec. 2023 was 49.17%.

ASKA Pharmaceutical Holdings Co had a gross margin of 49.17% for the quarter that ended in Dec. 2023 => Durable competitive advantage

During the past 3 years, the highest Gross Margin % of ASKA Pharmaceutical Holdings Co was 48.80%. The lowest was 46.55%. And the median was 47.28%.


ASKA Pharmaceutical Holdings Co Gross Profit Historical Data

The historical data trend for ASKA Pharmaceutical Holdings Co's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ASKA Pharmaceutical Holdings Co Gross Profit Chart

ASKA Pharmaceutical Holdings Co Annual Data
Trend Mar22 Mar23 Mar24
Gross Profit
26,351.00 28,584.00 30,664.00

ASKA Pharmaceutical Holdings Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6,218.00 7,463.00 7,723.00 8,445.00 7,033.00

Competitive Comparison of ASKA Pharmaceutical Holdings Co's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, ASKA Pharmaceutical Holdings Co's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ASKA Pharmaceutical Holdings Co's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ASKA Pharmaceutical Holdings Co's Gross Profit distribution charts can be found below:

* The bar in red indicates where ASKA Pharmaceutical Holdings Co's Gross Profit falls into.



ASKA Pharmaceutical Holdings Co Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

ASKA Pharmaceutical Holdings Co's Gross Profit for the fiscal year that ended in Mar. 2024 is calculated as

Gross Profit (A: Mar. 2024 )=Revenue - Cost of Goods Sold
=62843 - 32179
=30,664

ASKA Pharmaceutical Holdings Co's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=17176 - 8731
=8,445

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円30,664 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

ASKA Pharmaceutical Holdings Co's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=8,445 / 17176
=49.17 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


ASKA Pharmaceutical Holdings Co  (TSE:4886) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

ASKA Pharmaceutical Holdings Co had a gross margin of 49.17% for the quarter that ended in Dec. 2023 => Durable competitive advantage


ASKA Pharmaceutical Holdings Co Gross Profit Related Terms

Thank you for viewing the detailed overview of ASKA Pharmaceutical Holdings Co's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


ASKA Pharmaceutical Holdings Co (TSE:4886) Business Description

Traded in Other Exchanges
N/A
Address
2-5-1 Shibaura, Minato-ku, Tokyo, JPN, 108-8532
ASKA Pharmaceutical Holdings Co Ltd is engaged in the manufacturing, sale, import, export, clinical examinations and testing operations of pharmaceuticals, quasi-drugs, foods, veterinary drugs, feeds and feed additives and medical devices and related operations.

ASKA Pharmaceutical Holdings Co (TSE:4886) Headlines

No Headlines